About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
ecancer
ecancer.org
ecancer is a UK charity which provides accessible, high-quality educational content, free to the global oncology community. Our mission is to raise the standards of care for cancer patients across the world through education.
ELCC 2024
EAU 2024
ASCO GU 2024
ASCO GI 2024
AORTIC 2023
ASH 2023
SABCS 2023
ESMO 2023
Common Sense Oncology
WCLC 2023
ESMO WCGIC 2023
ASCO® 2023
EHA® 2023
ELCC 2023
ASCO GU 2023
BGICC 2023
ASCO GI 2023
SABCS 2022
ESMO 2022
WCLC 2022
EHA 2022
ASCO 2022
ASCO 2021
Lymphoma
Leukemia
Myeloma
GYN Cancers
Head&Neck Cancers
GI Cancers
Breast Cancers
GU Cancers
Lung Cancers
Skin Cancers
Basic Science
Supportive & Palliative Care
Business
Events
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
J
First Results of a Head-to-Head Trial of Acalabrutinib vs. Ibrutinib in Previously Treated CLL
By
ecancer
FEATURING
John Byrd
By
ecancer
FEATURING
John Byrd
396 views
October 5, 2022
0 Comments
Login to view comments.
Click here to Login
Featured Video
21:09
Exelixis
Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…
Feat.
S. Ratnam
Featured Video
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
Leukemia
07:33
ecancer
Epitope Editing Enables Targeted Immunotherapy of AML
Feat.
G. Casirati
04:14
ecancer
ALPINE: A Randomized Phase 3 Study of Zanubrutinib vs. Ibrutinib for…
Feat.
J. Brown
04:55
ecancer
First Results of a Head-to-Head Trial of Acalabrutinib vs. Ibrutinib…
Feat.
J. Byrd
04:36
ecancer
Safety & Efficacy of Asciminib for Heavily Pretreated Patients W…
Feat.
M. Mauro
10:41
ecancer
EHA 2021 Update on 1L Ibrutinib + Venetoclax for CLL/SLL: Primary An…
Feat.
J. Allan
05:12
ecancer
EHA 2021 Update on Venetoclax + Obinutuzumab in Untreated CLL: 4-yea…
Feat.
O. Al-Sawaf
07:02
ecancer
EHA 2021 Primary Analysis From the OPTIC Trial on CP-CML: A Dose-Ran…
Feat.
J. Cortés
07:36
ecancer
EHA 2021 Update on Fixed-Duration Ibrutinib and Venetoclax for 1L CL…
Feat.
A. Kater
05:52
ecancer
EHA 2021 Update on Blinatumomab for MRD-Positive B-Cell ALL
Feat.
N. Short
05:42
ecancer
EHA 2021 Update on Blinatumomab + Ponatinib for Ph+ ALL: Interim Res…
Feat.
N. Short
09:22
ecancer
EHA 2021 Update on KTE-X19, an Anti-CD19 CAR T-Cell Therapy for R/R …
Feat.
B. Shah
05:28
ecancer
2020 ASH Update on IDH 1/2-Mutated AML: Does Ven+Aza vs. Aza Mono Im…
Feat.
H. Kantarjian